A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis

Journal of Vector Borne Diseases

Volumn 45, Issue 4, 2008, Pages 287-291

  Nilforoushzadeh, M A ^a   Jaffary, F ^a   Ansari, N ^a   Siadat, Amir Hossein ^a   Nilforoushan, Z ^a   Firouz, A ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Meglumine antimoniate; Omeprazole; Placebo

Indexed keywords

MEGLUMINE ANTIMONATE; OMEPRAZOLE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN LEISHMANIASIS; SYSTEMIC THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; ANTIPROTOZOAL AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57749206229     PISSN: 09729062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hepburn NC. Cutaneous leishrnaniasis. Clin Exp Dermatol 2000; 25: 363-70.
2. Ardehali Sadrden. Leishmaniasis parasite and leishmaniasis. Tehran: Tehran University Publication Center 1985.
3. Asilian A. Cutaneous leishmaniasis. Chapter 1: Parasitology. Isfahan: Isfahan University of Medical Sciences Publication 1992; p. 18-9.
4. Nilforoushzadeh MA, Sadeghian G. Cutaneous leishmaniasis. Isfahan: Isfahan University of Medical Sciences Publication 2002; p. 114-6.
5. Ophir J, Krakowski A, Brenner S, Siegman-Igra Y, Michaeli D. Miconazole treatment for cutaneous leishmaniasis. J Infect Dis 1983; 148: 1168.
6. +-ATPase and gastric mucosa carbonic anhydrase enzyme in humans in vitro and in vivo experiments. J Pharmacol Exp Ther 1999; 290(2): 530-4.
7. Keshavarz AA, Bashiri H, Rahbar M. Omeprazole-based triple therapy with low versus high dose of clarithromycin plus amoxicillin for H. pylori eradication in Iranian population. World J Gastroenterol 2007; 13(6): 930-3.
8. Jiang S, Meadows J, Anderson SA, Mukkada AJ. Antileishmanial activity of the antiulcer agent omeprazole. Antimicrobial Agent Chemother 2002; 46: 2569-74.
9. Oliveira-Neto MP, Schubuch A, Mattos SM, Goncalves-Costa SC, Pirmez C. A low dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow up studies (up to 10 years). Am J Trop Med Hyg 1997; 57: 651-5.
10. Oliveira-Neto MP, Schubach A, Mattos SM, Goncalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dose (5 mg/kg/ d) and high dosage (20 mg/kg/d) antimony regimens. Pathol Biol (Paris) 1997; 45: 496-9.
11. Kochar DK, Saini G, Kochar SK, Bumb RA, Mehta RD, Sirohi P, Purohit SK. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis 2006; 43(4): 161-7.
12. Murakami I, Satoh H, Asano S, Maeda R. Role of capsaicin-sensitive sensory neurons and nitric oxide in the protective effect of lansoprazole, a proton pump inhibitor, on the gastric mucosa in rats. Jap J Pharmacol 1996; 72: 137-47.
13. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144: 4794-7.